Hyderabad
Hyderabad
“CliniPRP - 20” is a highly innovative, unique point of care technology platform that enables clinicians to separate whole blood components in a very short time and produce autologous Platelet Rich Plasma for clinical/research purpose.
Simple Point of care technology.
Intra operative support
Can prepare PRP in 30 min for treatment.
Evidence based therapeutic protocols and technology
PRP proven efficacy in various indications.
• Minimum steps required
• Easy separation with only one KIT
• Separation/isolation can be done with Dual Spin System
• Closed system / No air contamination possibility
• Gamma irradiation ensures no microbial contamination
• No chemical additives other than anticoagulant used during blood draw
• High concentration of platelets (8 ~ 10 times)
• Pure PRP/Leukocyte Rich PRP / PRGF can be prepared using single system following different protocols
• Controllability of the volume of plasma according to the treatment plan
• Consistently produces 2-3 ml of BMSC
Single use disposable kit
Helps in separation of patients own BMSC based on simple density gradient system using centrifuge
One system for various indications which require PRP therapy
PRP is blood plasma that has been enriched with platelets. As a concentrated source of autologous platelets, PRP contains several different growth factors and other cytokines that stimulate healing.
Contains high concentrations of platelet, leukocytes and other bioactivities, which play a prominent role in healing processes. It has been identified to improve cellular chemotaxis, proliferation and differentiation, angiogenesis, and production of extracellular matrix, but also responsible for stimulating defense mechanisms against infections.
There have been several methods reported in the literature on successfully delivering PRP to an injury site; most involve the creation of a platelet gel using thrombin or CaCl2. These PRP gels are then easily applied to wound sites through injection or topical application. However, studies have shown that the use of thrombin as a clotting agent can result in a rapid activation of platelets and a bolus release of growth factors with 70% of the growth factors released within 10 minutes of clotting and nearly 100% released within 1 hour. This ‘dumping’ method fails to maximize the cell-stimulating potential of the PRP growth factors as most are cleared before they can take effect.
The use of a sustained release method for delivering PRP growth factors and cytokines would be highly advantageous in a chronic wound state where senescent cells are prevalent, and could benefit from the sustained presence of stimulating factors.
